Elon Musk and Sam Altman cofounded OpenAI

Elon Musk and Sam Altman cofounded OpenAI, but now they're locked in a legal battle. Here's the history of their working relationship and feud.
Elon Musk asked a judge to block OpenAI's attempt to transition from nonprofit to for-profit. It's not the first time he's feuded with CEO Sam Altman.
Sam Altman on ChatGPT’s First Two Years, Elon Musk and AI Under Trump
AlexNet, created by Alex Krizhevsky, Sutskever and Geoffrey Hinton, used a deep convolutional neural network (CNN)—a powerful new type of computer program—to recognize images far more accurately than ever, kick-starting major progress in AI.
Sam Altman offers clues about where OpenAI is headed
In his latest blog post, Altman gave his take on what’s been happening behind the scenes at OpenAI—and what’s next for its technology.
Elon Musk pushes for OpenAI auction, Sam Altman sued by sister: Week in AI
Here's what you need to know this week about artificial intelligence in the Bay Area: Musk pushes for OpenAI auction, Altman sued by sister, Anthropic partially settles lawsuit with music publishers,
Musk Clashes With OpenAI CEO Sam Altman Over Trump-Supported Stargate AI Data Center Project
Elon Musk is clashing with OpenAI CEO Sam Altman over the Stargate artificial intelligence infrastructure project touted by President Donald Trump, the latest in a feud between the two billionaires th
Elon Musk clashes with OpenAI's Sam Altman over $500 billion AI project Donald Trump announced
Elon Musk, a close Donald Trump advisor questioned the value of the investment. Sam Altman responded, saying Elon Musk was “wrong, as you surely know”.
After fight with Sam Altman, Musk digs up OpenAI co-founder's tweet thanking Reid Hoffman for Trump's defeat in 2020
It all began with US President Donald Trump's announcement of a joint venture between OpenAI, SoftBank, and Oracle to create a $500 billion artificial intelligence initiative called Stargate. Musk claimed that the initiative did not have the amount they had announced.
'What Is Great For The Country Isn't Always What's Optimal For Your Companies': Sam Altman Lashes Out At Elon Musk Amid Stargate Squabble
Musk has been targeting Altman in the courts and publicly for months. The pair started OpenAI together nearly a decade ago as a nonprofit. Musk left OpenAI in 2018 and founded his
Barchart on MSN7h
Is This Sam Altman-Backed Nuclear Energy Stock a Buy, Sell, or Hold for 2025?
Oklo (OKLO) is a clean energy producer that aims to use advanced fission power plants to generate clean and affordable energy ...
The Information1h
Why Sam Altman Joined Forces With Larry Ellison and Took a Step Back From Microsoft
As 2024 was drawing to a close, OpenAI CEO Sam Altman faced two major problems. He wasn’t getting enough server capacity from Microsoft, his company’s biggest backer, to stay ahead of rivals ...
Sam Altman says Airbnb’s CEO and a ‘legendary’ VC saved OpenAI and ‘stopped me from making several mistakes’ after he was briefly fired in 2023
Immediately following his brief firing from OpenAI, Altman considered starting another AI company, something Chesky and Conway helped talk him out of.
Sam Altman's OpenAI backing initiative headed by several anti-Trump staff pushing liberal causes
Sam Altman's OpenAI is backing a new AI initiative from a group where John Kerry was a founding member that has voiced ...
AOL1mon
A look at the Gospel According to Sam Altman
And now, after years of stasis in Silicon Valley, we have Sam Altman ... product of unusual self-awareness. Altman, famously, was in the "first class" of Y Combinator, Silicon Valley's ur ...
The New York Times1mon
Sam Altman: The Next Frontier
2024 The New York Times Company Sam Altman is the co-founder and C.E.O ... Altman was president of the early-stage start-up accelerator Y Combinator from 2014 to 2019. In 2015, Altman ...
Sam Altman-backed Retro Biosciences to raise $1bn for longevity mission
Retro Biosciences is raising a $1bn round to fund the artificial intelligence-powered biotech’s mission to increase human lifespan by a decade, starting by getting its first drug into trials this year ...